1D-AL-LAD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
1D-AL-LAD, also known as 1-(1,2-dimethylcyclobutane-1-carbonyl)-AL-LAD, is a psychedelic drug of the lysergamide family related to AL-LAD.[1][2] It is thought to be a prodrug of AL-LAD similarly to how 1D-LSD is a prodrug of LSD.[1] 1D-AL-LAD was encountered online as a novel designer drug in 2023 and 2024.[1] It is said to have a dose of 100 to 300 μg orally, a time to peak effects of 2 to 2.5 hours, and a duration of 12 hours.[1] The drug is said have "half the intensity" of LSD, with its effects including psychedelic visuals among others.[1] Although 1D-AL-LAD has reported to have been sold, some or all of the sold product appears to have actually been mislabeled 1T-AL-LAD.[2][3] 1D-AL-LAD is not an explicitly controlled substance in the United States[4] or in Canada.[5]
- None
 | |
| Clinical data | |
|---|---|
| Other names | 1D-AL-LAD; 1-(1,2-Dimethylcyclobutane-1-carbonyl)-AL-LAD; 1-(1,2-Dimethylcyclobutanecarbonyl)-6-allyl-nor-LSD |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | Peak: 2–2.5 hours[1] |
| Duration of action | 12 hours[1] |
| Chemical and physical data | |
| Formula | C29H36N3O2 |
| Molar mass | 458.626 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
